<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; raises</title>
	<atom:link href="http://www.tapanray.in/tag/raises/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Grant of Compulsory License for Bayer’s Nexavar in India raises more questions than answers</title>
		<link>http://www.tapanray.in/grant-of-compulsory-license-for-bayers-nexavar-in-india-raises-more-questions-than-answers/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=grant-of-compulsory-license-for-bayers-nexavar-in-india-raises-more-questions-than-answers</link>
		<comments>http://www.tapanray.in/grant-of-compulsory-license-for-bayers-nexavar-in-india-raises-more-questions-than-answers/#comments</comments>
		<pubDate>Mon, 26 Mar 2012 00:00:05 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[answers]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CGPDTM]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[controller]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[questions]]></category>
		<category><![CDATA[raises]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[than]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=116</guid>
		<description><![CDATA[On March 12, 2012, the Patent Office of India, in its landmark ruling, granted its first ever Compulsory License (CL) for Bayer’s patented kidney and liver cancer drug Nexavar (Sorafenib), to the generic pharma player Natco, broadly citing the following &#8230; <a href="http://www.tapanray.in/grant-of-compulsory-license-for-bayers-nexavar-in-india-raises-more-questions-than-answers/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/grant-of-compulsory-license-for-bayers-nexavar-in-india-raises-more-questions-than-answers/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
